Skip to main content

Table 1 A selection of albumin-based systems in clinical trials and marketed products

From: Albumin-based drug delivery: harnessing nature to cure disease

Attachment

Name

Disease

Drug type

Clinical status

Company

Ref

Non-covalent/reversible association

Levemir®

Diabetes type 1 and 2

Insulin detemir

Marketed

Novo Nordisk

[123, 124]

Victoza®

Diabetes type 2

GLP-1

Marketed

Novo Nordisk

[123]

Ozoralizumab

Rheumatoid arthritis

Antibody derivative

Phase II completed

Ablynx

[90]

Covalent

MTX-HSA

Cancer and autoimmune diseases

Methotrexate

Phase II

Access Pharmaceuticals Inc.

[26, 119, 125, 126]

Aldoxorubicin

Cancer

Doxorubicin

Phase I completed

CytRx, Inc.

[110, 127]

 

CJC-1134

Diabetes type 2

Exendin-4

Phase II

ConjuChem

[11, 128–131]

Genetic fusion

Eperzan/Tanzeum

Diabetes type 2

GLP-1

Marketed

Glaxo Smith Kline

[132–134]

N/A

Hemophilia

FVIIa

Phase I completed

CSL Behring GmbH

[135–138]

N/A

Hemophilia B

rIX-FP

Phase III completed

CSL Behring GmbH

[139]

Albuferon®/Zalbin/Jouleferon

Hepatitis C

INFalpha-2b

Phase III completed, Development ceased

Human Genome Sciences in collaboration with Novartis

[11, 140]

Micro-/Nanoparticle

Abraxane®

Cancer

Paclitaxel

Marketed

Celgene

[141]

ABI-008

Cancer

Docetaxel

Phase I/II

Celgene

[95]

ABI-009

Cancer

Rapamycin

Phase I/II

Celgene

[96]

ABI-010

Cancer

HSP90 Inhibitor

Withdrawn before enrollment

Celgene

[97]

99mTc-Albures

Diagnostic purpose

Technetium-99

Marketed

GE Healthcare

 

99mTc-Nanocoll

Diagnostic purpose

Technetium-99

Marketed

GE Healthcare

Â